At a Glance
Kurma Partners is a venture capital firm based in Paris, France founded in 2009. Avec les meilleurs acteurs européens de la recherche académique, nous avons tissé un solide réseau de partenaires pour transformer leurs découvertes scientifiques disruptives en médicaments ou en dispositifs médicaux de pointe pour diagnostiquer et soigner des patients atteints de maladies graves ou incurables à ce jour. Nous avons l'ambition de travailler avec les principaux instituts de recherche européens, pour construire l’industrie de santé de demain. Pour cela, nous avons développé une app The firm focuses on Pre-Seed, Seed, Series A, Series B+ investments across sectors including Aerospace & Defense, Digital Health, Other, Consumer, Fintech. Notable portfolio companies include Carmat, Cynbiose, DNA Script, Genfit and TreeFrog Therapeutics. Invests in early-stage life sciences companies developing innovative therapeutics, medical devices, and diagnostic technologies.
“Invests in early-stage life sciences companies developing innovative therapeutics, medical devices, and diagnostic technologies.”
Kurma Partners primarily invests at the Pre-Seed, Seed, Series A, Series B+ stages. This means they focus on companies that are at the earliest idea or prototype phase.
Kurma Partners is headquartered in Paris, France. Many of their portfolio companies are also based in this region, though they invest across geographies.
Kurma Partners focuses on investments in Aerospace & Defense, Digital Health, Other, Consumer, Fintech. Their portfolio reflects deep expertise and networks within these sectors.
Kurma Partners's typical investment check size ranges from $. to $.. Actual amounts may vary based on the stage, sector, and specific opportunity.
Kurma Partners manages approximately $300M in assets under management (AUM) across their funds.
